Crispr Therapeutics AG last reported quarterly results on Nov 2, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $12.7 million (+1325.1% year over year) and diluted EPS of -$1.15. It usually reports 33–43 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 33–43 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 2, 2026
33 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
13
+1325.1%
|
-111
-4.7%
|
-1.15
+1.7%
|
|
Aug 3, 2026
34 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
10
+1041.4%
|
-91
+56.3%
|
-0.94
+60.8%
|
|
May 4, 2026
34 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1
+68.6%
|
-123
+9.6%
|
-1.28
+19.0%
|
|
Feb 12, 2026
43 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1
-97.6%
|
-131
-250.1%
|
-1.37
-214.1%
|
|
Nov 10, 2025
41 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1
+47.7%
|
-106
-23.9%
|
-1.17
-15.8%
|
|
Aug 4, 2025
35 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1
+72.5%
|
-209
-65.0%
|
-2.40
-61.1%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
1
+71.6%
|
-136
-16.6%
|
-1.58
-10.5%
|
|
Feb 11, 2025
42 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
36
-82.3%
|
-37
-141.8%
|
-0.44
-138.9%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRSP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Zug
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1674416
- Former names
- CRISPR Therapeutics AG (until Nov 2, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.